With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...
They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
6d
Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
SINGAPORE: In a bid to bolster Singapore’s healthcare resilience, the country has launched Asia’s first fully automated mRNA ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback